• Recruiting

NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With RRMM

Updated: Jun 21

NCT03309111: Phase 1: ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma


ISB1342

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.


Sponsor

Ichnos Sciences SA


Collaborator

Glenmark Pharmaceuticals S.A.

 

ClinicalTrials.gov Identifier: NCT03309111


Official Title: A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects With Previously Treated Multiple Myeloma

First Posted : October 13, 2017


Click here to see details on ClinicalTrials.gov

 

Biological: ISB 1342


ISB 1342 (formerly known as GBR 1342)


Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342 (Code C147563)


Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342 (Code C147563)


Anti-CD38 x Anti-CD3 Bispecific Monoclonal Antibody GBR 1342

Anti-CD38/Anti-CD3 Bispecific Monoclonal Antibody GBR 1342

Anti-CD38/CD3 Bispecific Monoclonal Antibody GBR 1342

BEAT GBR 1342

CD38xCD3 BsAb GBR 1342

GBR 1342

GBR-1342

GBR1342

 

Locations

United States, Maryland

United States, Minnesota

United States, New York

United States, North Carolina

United States, Tennessee

Europe

France


Posts Archive